

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Michael N. HELMUS et al.

Serial No.: 10/781,932

Examiner: Unassigned

Confirmation No.: 9710

Art Unit: 1614

Filed: February 20, 2004

For: BIOMATERIALS FOR ENHANCED HEALING

U.S. Patent and Trademark Office  
220 20<sup>th</sup> Street S.  
Customer Window, **Mail Stop Sequence**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

TRANSMITTAL OF DOCUMENTS

Enclosed are the following documents in response to the Notice to Comply mailed November 2, 2004 for the above-identified application:

- ☒ Amendment In Response To Notice Under 37 C.F.R. §§1.821-825
- ☒ Copy of Notice To Comply With Requirements For Patent Applications  
Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures
- ☒ Statement To Support Filing And Submission In Accordance with 37 C.F.R.  
§§1.821-825
- ☒ Sequence Listing
- ☒ Computer Readable Copy of Sequence Listing (disk)
- ☒ Return receipt postcard
- ☐ Check in the amount of \$        for the total fee as calculated below
- ☐ Other:

The fee has been calculated as follows:

	NO. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY FILED	EXTRA CLAIMS	RATE	FEE
Total Claims	37	- 37 =	0	x \$50.00	0.00
Independent Claims	10	- 10 =	0	x \$200.00	0.00
If multiple dependent claims are presented, add \$360.00					
Total Amendment Fee					0.00
If small entity status is applicable, subtract 50% of Total Amendment Fee					
Other fees: (specify)					
<b>TOTAL FEE DUE</b>					0.00

☐ A check for the total fee is attached.

☐ Please charge \$ to Deposit Account No. 50-1283 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37

C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any


overpayment, to Deposit Account No. 50-1283.

Dated: December 23, 2004

Cooley Godward LLP  
ATTN: Patent Group  
One Freedom Square  
Reston Town Center  
11951 Freedom Drive  
Reston, Virginia 20190-5656  
Tel: (703) 456-8000  
Fax: (703) 456-8100

Respectfully submitted,  
COOLEY GODWARD LLP

By:

  
Timothy D. Ford  
Reg. No. 47,567



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/781,932	02/20/2004	Michael N. Helmus	BSCI-006/00US

22903  
 COOLEY GODWARD LLP  
 ATTN: PATENT GROUP  
 11951 FREEDOM DRIVE, SUITE 1700  
 ONE FREEDOM SQUARE- RESTON TOWN CENTER  
 RESTON, VA 20190-5061

CONFIRMATION NO. 9710

## FORMALITIES LETTER



\*OC000000014265628\*

Date Mailed: 11/02/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.


**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>
- For Patent Software Program Help, call (571) 272-2510 or email [mark.spencer@uspto.gov](mailto:mark.spencer@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria VA 22313-1450

---

*A copy of this notice MUST be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART I - ATTORNEY/APPLICANT COPY